GreenLight SPAC Presentation Deck

Summary Risk Factors Risks relating to the proposed business combination (cont'd): • The consummation of the merger is subject to a number of conditions and if those conditions are not satisfied or waived, the merger agreement may be terminated in accordance with its terms and the merger may not be completed. ● If the Merger benefits do not meet the expectations of investors or securities analysts, the market price of ENVI's securities or, following the consummation of the Merger, the combined company's securities may decline. • Potential legal proceedings in connection with the Merger, the outcomes of which are uncertain, could delay or prevent the completion of the Merger. • If ENVI's due diligence investigation of the Company's business was inadequate and material risks are not uncovered, stockholders of ENVI following the Merger could lose some or all of their investment. • New GreenLight's stock price may change significantly following the merger and you could lose all or part of your investment as a result. • Because there are no current plans to pay cash dividends on New GreenLight Common Stock for the foreseeable future, you may not receive any return on investment unless you sell your common stock for a price greater than that which you paid for it. • Future sales, or the perception of future sales, by New GreenLight or its stockholders in the public market following the merger could cause the market price for New GreenLight Common Stock to decline. • Certain of New GreenLight's stockholders, including the Sponsor, may engage in business activities which compete with New GreenLight or otherwise conflict with New GreenLight's interests. • There is no guarantee that a ENVI public stockholder's decision whether to redeem their shares for a pro rata portion of the Trust Account will put such stockholder in a better future economic position. Redemptions by ENVI public stockholders will result in less funding being available to New GreenLight and may cause a condition to the merger to fail. Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. 56

View entire presentation